Algeta oversubscribed on $80m growth deal
GlobalCapital, is part of the Delinian Group, DELINIAN (GLOBALCAPITAL) LIMITED, 4 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 15236213
Copyright © DELINIAN (GLOBALCAPITAL) LIMITED and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement
Equity

Algeta oversubscribed on $80m growth deal

Norwegian cancer drug firm Algeta launched a Nkr390m-Nkr470m ($67m-$82m) bookbuild on Monday evening in a capital raise to build up its US sales operation and to fund research and development, while one of its leading shareholders sells down a small portion of its holding.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login
Gift this article